Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 4/20 | 0.48 |
| ▸ | BRAF | P15056 | 4/20 | 0.47 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.44 |
| ▸ | TYK2 | P29597 | 6/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27033947 | 0.87 | PIK3C3 (0.39) | ACVRL1BRAFMETTL3PIK3C3TYK2 | |
| SCHEMBL24729640 | 0.87 | METTL3 (0.43) | METTL3KLKB1 | |
| SCHEMBL24739071 | 0.86 | METTL3 (0.43) | METTL3KLKB1 | |
| SCHEMBL27033957 | 0.86 | KLKB1 (0.40) | ACVRL1BRAFMETTL3TYK2JAK2 | |
| SCHEMBL29958278 | 0.86 | KLKB1 (0.40) | ACVRL1BRAFMETTL3TYK2JAK2 | |
| SCHEMBL29305553 | 0.86 | METTL3 (0.46) | METTL3ABL1KLKB1 | |
| SCHEMBL24738308 | 0.84 | KLKB1 (0.39) | ACVRL1METTL3TYK2KLKB1 | |
| SCHEMBL29879563 | 0.84 | KLKB1 (0.39) | ACVRL1METTL3TYK2KLKB1 | |
| SCHEMBL29302924 | 0.84 | KLKB1 (0.39) | ACVRL1METTL3TYK2KLKB1 | |
| SCHEMBL29304996 | 0.84 | ACVRL1 (0.44) | ACVRL1BRAFPIK3C3TYK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |